About BioLineRx
BioLineRx is a publicly listed company based in Modi'in-maccabim-re'ut (Israel) founded in 2003 by Avi Molcho. Clinical stage biopharmaceutical development company. BioLineRx has raised $23 million across 6 funding rounds from investors including Novartis, Teva Pharmaceuticals and Giza Venture Capital. The company has 28 employees. BioLineRx has completed 1 acquisition, including Agalimmune. Its chief executive, as recorded, is Philip A Serlin. BioLineRx offers products and services including APHEXDA. Its focus areas include Diversified Pharmaceuticals. Its legal entity is BioLineRx Ltd.
Company details
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. It in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical andor clinical stages, and then partners with pharmaceutical companies for advanced clinical development andor commercialization. BioLineRxs pipeline currently consists of six clinical stage therapeutic candidates which could be used in case of acute myeloid leukemia (AML), celiac disease, non-surgical removal of skin lesions, inflammatory bowel disease, interferon-free treatment for Hepatitis C, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients. It also has a multi-year strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates.
- Headquarters Modi'in-maccabim-re'ut, Israel
- Employees 28
- Founders Avi Molcho
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website biolinerx.com
- Social LinkedIn X Facebook
- Legal Name Biolinerx Ltd.
- Annual Revenue$1.28 M (USD)-96.2as on Dec 31, 2025
- Net Profit-$1.27 M (USD)88.13as on Dec 31, 2025
- EBITDA-$10.56 M (USD)40.55as on Dec 31, 2025
- Total Equity Funding$23M (USD)
in 6 rounds
- Latest Funding Round$10M (USD), Post-IPO
Dec 2014
- InvestorsNovartis
& 7 more
- Employee Count28
- Investments & Acquisitions
Products & Services of BioLineRx
BioLineRx offers a comprehensive portfolio of products and services, including APHEXDA.
FDA-approved therapy for stem cell mobilization in multiple myeloma and related conditions.
Funding Insights of BioLineRx
BioLineRx has successfully raised a total of $23M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23M
- Total Rounds 6
- Last Round Post-IPO — $10M
- First Round $14M
(Jun 2004)
- Investors Count 8
All 6 funding rounds of BioLineRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $10M | Post-IPO | – | – | |
| Mar 2014 | $24.1M | Post-IPO | – | – | – |
| Feb 2012 | $15M | Post-IPO | – | – | – |
| Sep 2005 | $9M | Series A | – | – | |
| Dec 2004 | $21M | Grant | – | – | – |
| Jun 2004 | $14M | Series A | – | – |
8 investors in total: 7 institutional and 1 angel.
Investors in BioLineRx
BioLineRx has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Novartis, Teva Pharmaceuticals and Giza Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm investing in seed & early stage companies in Israel & the US | gizavc.com | Tel Aviv, Israel | ||
Venture capital investments in tech and healthtech sectors through dedicated funds. | pitango.com | |||
Early & late stage sector-agnostic VC firm investing in the US, Asia and Middle East | star-ventures.com | Herzliya, Israel | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel | |
| hadassah-med.com | ||||
Economic and urban development in Jerusalem is facilitated. | 1988 | jda.gov.il | Jerusalem, Israel | |
YZ Yehuda Zisapel | Israeli entrepreneur, angel investor, co-founder of RAD Group, active in tech startups | unknown_35be8f068bd442cfa |
Investor details for BioLineRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioLineRx
23 people are tracked at BioLineRx (12 in leadership, 7 in board & advisors, 4 in team); the tracked headcount is 28.
| Name | Role | Group |
|---|---|---|
Avi Molcho | Co-Founder | Leadership |
Philip A Serlin | CEO | Leadership |
Liron Shemesh-Darvish | Senior Director, Head of Preclinical Development | Leadership |
Mali Zeevi | Chief Financial Officer | Leadership |
Jael Birenberg | Senior Director, Head of RA, QA & PhV | Leadership |
Ella Sorani | Chief Development Officer | Leadership |
Irit Gliko-Kabir | VP, Clinical Operations | Leadership |
Marj Fackovec | Head Of US Human Resources | Leadership |
Ofer Porat | Senior Director Human Resources | Leadership |
Nava Rabin | Senior Director Of Quality Assurance | Leadership |
Bryce Emery King | National Sales Director | Leadership |
Gideon Stein | Senior Director of Clinical Development Strategy | Leadership |
Rami Dar | Board Memebr, Chair Of Audit Committee | Board & advisors |
Rafael Hofstein | Board Member | Board & advisors |
BJ Bormann | Board Member | Board & advisors |
Sandra Panem | Board Member | Board & advisors |
Avraham Molcho | Board Member | Board & advisors |
Aharon Schwartz | Chairman | Board & advisors |
Michael J. Anghel | Board Member | Board & advisors |
Ravit Shemesh Dvash | Quality Assurance Manager | Team |
3 more people are available in the full profile.
Complete people profiles for BioLineRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioLineRx
BioLineRx is a publicly listed company on the TASE with ticker symbol BLRX in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Apr 2015
- Listed onFRA: BLRX
- Listed entityBioLineRX Ltd.
- Exchange sectorHealth technology
- ISINIL0011015182
- Share price1.30 ILA (+8.33% on the day) · 2026-10-14
- Market capitalisation35,843,157.00 ILA
- EPS (diluted, trailing year)-0.01 ILA
- Volume (last session)51,740
Financials of BioLineRx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.1M ILS | -4.0M ILS | -33.7M ILS |
| 2024 | 107.1M ILS | -34.1M ILS | -56.6M ILS |
| 2023 | 17.7M ILS | -223.6M ILS | -153.4M ILS |
| 2022 | -83.8M ILS | -95.8M ILS | |
| 2021 | -87.4M ILS | -77.8M ILS |
Detailed financial statements for BioLineRx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioLineRx
BioLineRx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Agalimmune.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Synthetic alpha-Gal immunotherapy is developed for solid tumors. | agalimmune.com | London, United Kingdom | 2013 | Mar 2017 | $6M |
Complete acquisition details for BioLineRx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioLineRx
5 dated milestones of BioLineRx across 14 years, from founding to its latest funding, stage changes and deals.
- Founded BioLineRx is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Post-IPO, of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Agalimmune.
Web traffic of BioLineRx
The website of BioLineRx (biolinerx.com) receives about 5.1K visits a month and ranks #4,098,574 among all websites worldwide, #5,120 in Biotechnology and Pharmaceuticals.
- Monthly visits5.1K
▲ 15.1% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,098,574
among all websites
- Category rank#5,120
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit54 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with BioLineRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biomodels.com | 100% | 2.5K | #9,156,523 | View details | |
symbionresearch.com | symbionresearch.com | 99% | – | ||
| irisys.com | 99% | View details | |||
| certara.com | 62% | 98.2K | #495,649 | View details | |
| newtbdrugs.org | 62% | #3,185,292 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for BioLineRx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biolinerx
Complete news archive for BioLineRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioLineRx
BioLineRx was founded in 2003 and raised its 1st funding round 1 year after it was founded.
BioLineRx is headquartered in Modi'in-maccabim-re'ut, Israel. It is registered at Modi'in-maccabim-re'ut, Central District, Israel.
Philip A Serlin is the CEO of BioLineRx, as recorded in our data.
BioLineRx is a funded company, having raised a total of $23M across 6 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Jun 2004.
BioLineRx has 28 employees.
Annual revenue of BioLineRx is $1.28M as on Dec 31, 2025.
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. It in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical andor clinical stages, and then partners with pharmaceutical companies for advanced clinical development andor commercialization. BioLineRxs pipeline currently consists of six clinical stage therapeutic candidates which could be used in case of acute myeloid leukemia (AML), celiac disease, non-surgical removal of skin lesions, inflammatory bowel disease, interferon-free treatment for Hepatitis C, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients. It also has a multi-year strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates.
BioLineRx offers APHEXDA.
Yes, BioLineRx is publicly traded on TASE under the ticker symbol BLRX.
BioLineRx has made 1 acquisition, including Agalimmune.
BioLineRx has 8 investors. Key investors include Novartis, Teva Pharmaceuticals, Giza Venture Capital, Pitango, and Hadassah.
BioLineRx operates through Biolinerx Ltd..